✦ LIBER ✦

1468 POTENTIAL OF PREBIOPSY MULTIPARAMETRIC MAGNETIC RESONANCE IMAGING TO REDUCE INITIAL BIOPSIES IN MEN WITH SUSPECTED CLINICALLY LOCALIZED PROSTATE CANCER

✍ Scribed by Numao, Noboru; Yoshida, Soichiro; Ishii, Chikako; Komai, Yoshinobu; Kijima, Toshiki; Yokoyama, Minato; Ishioka, Junichiro; Matsuoka, Yoh; Koga, Fumitaka; Saito, Kazutaka; Masuda, Hitoshi; Fujii, Yasuhisa; Kawakami, Satoru; Kihara, Kazunori

Book ID: 122751198
Publisher: Lippincott Williams and Wilkins
Year: 2013
Tongue: English
Weight: 78 KB
Volume: 189
Category: Article
ISSN: 0022-5347
DOI: 10.1016/j.juro.2013.02.2933

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Usefulness of Pre-biopsy Multiparametric

Usefulness of Pre-biopsy Multiparametric Magnetic Resonance Imaging and Clinical Variables to Reduce Initial Prostate Biopsy in Men with Suspected Clinically Localized Prostate Cancer

✍ Numao, Noboru; Yoshida, Soichiro; Komai, Yoshinobu; Ishii, Chikako; Kagawa, Mako 📂 Article 📅 2013 🏛 Lippincott Williams and Wilkins 🌐 English ⚖ 236 KB

830 Potential of prebiopsy MRI to reduce

830 Potential of prebiopsy MRI to reduce biopsies in men with suspected clinically localized prostate cancers in the repeat biopsy setting

✍ Ishikawa, Y.; Numao, N.; Yoshida, S.; Ishii, C.; Kijima, T.; Nakanishi, Y.; Ishi 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 200 KB

Preoperative 3-Tesla Multiparametric End

Preoperative 3-Tesla Multiparametric Endorectal Magnetic Resonance Imaging Findings and the Odds of Upgrading and Upstaging at Radical Prostatectomy in Men With Clinically Localized Prostate Cancer

✍ Hegde, John V.; Chen, Ming-Hui; Mulkern, Robert V.; Fennessy, Fiona M.; D'Amico, 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 172 KB

Can multiparametric magnetic resonance i

Can multiparametric magnetic resonance imaging predict upgrading of transrectal ultrasound biopsy results at more definitive histology?11Mohamed Abd-Alazeez receives funding from the Egyptian government. Mark Emberton and Hashim U. Ahmed receive funding from USHIFU and Advanced Medical Diagnostics for clinical trials. Mark Emberton is a paid consultant for Steba Biotech, USHIFU and Sanofi-Aventis. Mark Emberton has received research support by GSK for a study evaluating the role of MRI in men with prostate cancer. Mark Emberton and Hashim Ahmed have previously received medical consultancy fees from GE Healthcare/Oncura and Hashim Ahmed previously from Steba Biotech. Mark Emberton is a medical director of Mediwatch PLC. Hashim Uddin Ahmed and Mark Emberton receive funding from the Medical Research Council, the NIHR-HTA, NIHR-i4i, the US NIH/NCI, Pelican Cancer Foundation, Prostate Cancer UK, and St Peter׳s Trust. This work was part funded by research support for Mark Emberton and Alex Kirkham from the UK National Institute of Health Research UCLH/UCL Comprehensive Biomedical Research Centre, London, UK.

✍ Abd-Alazeez, Mohamed; Ahmed, Hashim U.; Arya, Manit; Allen, Clare; Dikaios, Niko 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 415 KB